SOPHiA GENETICS S.A. logo SOPH - SOPHiA GENETICS S.A.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 6
HOLD 1
SELL 0
STRONG
SELL 0
| PRICE TARGET: $7.50 DETAILS
HIGH: $8.00
LOW: $7.00
MEDIAN: $7.50
CONSENSUS: $7.50
UPSIDE: 32.74%

Stock News

SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting

SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting

Shareholders adopt all proposals, co-founder Dr. Jurgi Camblong elected as Executive Chairman of the Board, Ross Muken elected as new member of the Board ahead of his appointment as CEO effective July 1, 2026 ROLLE, Switzerland, June 22, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today announced that its 2026 Annual General Meeting of shareholders adopted all proposals on the agenda, electing Dr. Jurgi Camblong as the Executive Chairman of the Board of Directors with 99.79% of the votes, and Ross Muken as a member of the Board of Directors for the first time with 99.88% of the votes. Mr. Muken will assume the role of Chief Executive Officer, effective July 1, 2026.

Jun 22, 2026 04:25 AM • prnewswire.com
SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares

SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares

BOSTON and ROLLE, Switzerland, June 19, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the closing of its previously announced underwritten public offering with total gross proceeds of $57.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. As a result of strong investor demand, the offering was oversubscribed, and the underwriters fully exercised their option to purchase an additional 1,578,900 ordinary shares at the public offering price, less the underwriting discounts and commissions.

Jun 19, 2026 04:00 AM • prnewswire.com
SOPHiA Genetics: Strong Growth Meets A Critical Execution Phase

SOPHiA Genetics: Strong Growth Meets A Critical Execution Phase

SOPHiA GENETICS is approaching an inflection point in precision medicine, leveraging AI-driven genomic analysis as sequencing costs decline and data complexity rises. SOPH's platform benefits from a self-reinforcing data flywheel, with 2.5 million genomic profiles and 537 institutions using SOPHiA DDM across 75 countries. Revenue grew 22% year-over-year to $21.7M in 1Q26, with 117% net dollar retention and adjusted gross margin of 75.4%, but profitability remains a key watchpoint.

Jun 18, 2026 04:22 AM • seekingalpha.com
SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares

SOPHiA GENETICS Announces Pricing of $50 Million Public Offering of Ordinary Shares

BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the pricing of its previously announced underwritten public offering of 10,526,000 ordinary shares at a public offering price of $4.75 per ordinary share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company are expected to be approximately $50 million.

Jun 16, 2026 05:21 PM • prnewswire.com
SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares

SOPHiA GENETICS Announces Proposed Public Offering of Ordinary Shares

BOSTON and ROLLE, Switzerland, June 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, announced today the commencement of a proposed underwritten public offering of its ordinary shares. The Company also expects to grant the underwriters an option to purchase up to an additional 15% of the ordinary shares at the public offering price, less the underwriting discount.

Jun 16, 2026 12:20 PM • prnewswire.com
SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting

SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting

Ross Muken to assume the role of Chief Executive Officer effective July 1, 2026; Co-founder Dr. Jurgi Camblong nominated for election as Chairman of the Board BOSTON and ROLLE, Switzerland, June 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today confirmed, ahead of its 2026 Annual General Meeting (AGM) scheduled for June 18, 2026, the leadership changes first announced in January 2026. The Board has appointed Ross Muken, currently President, as Chief Executive Officer, effective July 1, 2026, and nominated him for election as a member of the Board of Directors.

Jun 10, 2026 04:00 AM • prnewswire.com
SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center

SOPHiA GENETICS Signs Strategic Collaboration MOU with Leading Global Cancer Center

SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center Aim to Establish Precision Medicine Hub for the Next Generation of Precision Oncology NEW YORK, June 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced that the company has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) relating to the formation of a joint venture between the two institutions. The joint venture aims to build upon the strength of MSK innovation in clinical diagnostics and SOPHiA GENETICS's Ai platform to potentially discover, develop, and deploy a new generation of precision oncology to patients around the world.

Jun 04, 2026 04:00 AM • prnewswire.com
Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.

Synnovis and SOPHiA GENETICS Partner to Bring Blood-based Cancer Testing to Patients Across the U.K.

LONDON, May 13, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers, to bring liquid biopsy testing to lung and breast cancer patients across the U.K. as part of NHS England's 'revolutionary blood test-first' program. Synnovis, a major provider for England's South East Genomic Medicine Service, worked with SOPHiA GENETICS to launch the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™.

May 13, 2026 01:00 AM • prnewswire.com
SOPHiA GENETICS Reports First Quarter 2026 Results

SOPHiA GENETICS Reports First Quarter 2026 Results

BOSTON and ROLLE, Switzerland, May 5, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medicine, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Results Revenue was $21.7 million, up 22% year-over-year Gross margin was 68.0% on a reported basis and 75.4% on an adjusted basis, compared to 68.7% reported and 75.7% adjusted in the prior year period IFRS net loss was $19.3 million, an increase of 11% year-over-year; Adjusted EBITDA loss was $9.2 million, improving 3% year-over-year "We started 2026 strong, delivering 22% year-over-year revenue growth and a record 108,000 genomic analyses on SOPHiA DDMTM," said Jurgi Camblong, PhD.

May 05, 2026 02:45 AM • prnewswire.com
SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026

SOPHiA GENETICS to Announce Financial Results for First Quarter 2026 on May 5, 2026

BOSTON and ROLLE, Switzerland, April 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the first quarter 2026 before U.S. markets open on Tuesday, May 5, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.

Apr 21, 2026 04:00 AM • prnewswire.com
Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026

Mount Sinai Health System and SOPHiA GENETICS Announce Collaboration to Advance Precision Cancer Care from AACR 2026

SAN DIEGO and NEW YORK, April 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the leading academic health systems in the United States, will adopt the AI-powered SOPHiA DDM™ Platform to advance cancer research and enhance genomic testing capabilities. Mount Sinai, a National Cancer Institute-designated Comprehensive Cancer Center in New York City, supports care for more than 4,000 oncology patients annually.

Apr 16, 2026 04:00 AM • prnewswire.com
SOPHiA GENETICS (NASDAQ:SOPH) & Hims & Hers Health (NYSE:HIMS) Financial Comparison

SOPHiA GENETICS (NASDAQ:SOPH) & Hims & Hers Health (NYSE:HIMS) Financial Comparison

Hims and Hers Health (NYSE: HIMS - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Valuation and Earnings This table compares

Mar 14, 2026 09:58 PM • defenseworld.net
SOPHiA GENETICS Q4 Earnings Call Highlights

SOPHiA GENETICS Q4 Earnings Call Highlights

SOPHiA GENETICS (NASDAQ: SOPH) executives highlighted accelerating commercial momentum, expanding platform capabilities, and improved profitability outlook during the company's fourth-quarter and full-year 2025 earnings call. Management also discussed leadership changes, major customer wins, and progress in both its clinical and biopharma businesses. 2025 performance and platform scale Co-founder and CEO Dr. Jurgi Camblong described 2025 as

Mar 04, 2026 09:34 PM • defenseworld.net
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results

SOPHiA GENETICS Reports Fourth Quarter and Full Year 2025 Results

BOSTON and ROLLE, Switzerland, March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Results Revenue was $21.7 million, up 22% year-over-year Gross margin was 67.7% on a reported basis and 73.9% on an adjusted basis, compared to 68.2% reported and 74.2% adjusted in the prior year period IFRS net loss was $19.2 million, an increase of 27% year-over-year; Adjusted EBITDA loss was $9.9 million, an increase of 9% year-over-year Full Year 2025 Financial Results Revenue was $77.3 million, up 19% year-over-year Gross margin was 67.4% on a reported basis and 74.2% on an adjusted basis, compared to 67.4% reported and 72.8% adjusted in the prior year period IFRS net loss was $79.0 million, an increase of 26% year-over-year; Adjusted EBITDA loss was $41.5 million, an increase of 3% year-over-year "We finished 2025 strong, with Q4 revenue growing 22% and full-year revenue increasing 19% year-over-year, as our growth momentum continues to accelerate," said Jurgi Camblong, Chief Executive Officer and co-founder of SOPHiA GENETICS.

Mar 03, 2026 01:45 AM • prnewswire.com
SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference

SOPHiA GENETICS to Present at the 46th Annual TD Cowen Health Care Conference

BOSTON and ROLLE, Switzerland, Feb. 25, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced that leadership will present at TD Cowen's 46th Annual Health Care Conference in Boston. Jurgi Camblong, Chief Executive Officer and co-founder of SOPHiA GENETICS, and Ross Muken, President of SOPHiA GENETICS, will participate in a fireside chat on Wednesday, March 4, 2026, at 10:30 am EST / 4:30 pm CET.

Feb 25, 2026 03:00 AM • prnewswire.com

Price Targets